Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
ConditionsBreast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, MetastaticBreast CarcinomaBreast DiseasesBreast NeoplasmsBreast Neoplasms, MaleBreast CancerBreast Cancer With Metastatic Bone DiseaseBreast CancersBreast NeoplasmBreast TumorsHR+ HER2- Men, Pre/Postmenopausal Advanced Breast CancerHR+ Advanced or Metastatic Breast CancerHR+/HER2- Breast CancerHRpos Breast NeoplasmsHR-positive, HER2-negative Advanced Breast CancerHR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerHR-positive Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive Breast AdenocarcinomaHormone Receptor Positive Breast CarcinomaHormone Receptor Positive Breast NeoplasmsHormone Receptor Positive HER-2 Negative Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastHormone Receptor Positive Metastatic Breast CancerHormone Receptor Positive, HER2 Negative Breast CancerHormone Receptor Negative Breast CancerHormone Receptor Positive, HER2-negative, Advanced Breast CancerHormone Receptor Positive Breast CancerHormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast CancerHormone Receptor Positive, HER2-negative NeoplasmsHormone Receptor Positive, HER2-low NeoplasmsHormone Receptor Positive (HR+), HER2-negative Breast CancerHormone Receptor (HR)-Positive Breast CancerHormone Receptor-Positive, HER2-Negative Metastatic Breast CancerPalbociclibRibociclibAbemaciclibCDK4/6 InhibitorCDK4/6 Inhibitors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano